oncomed

What oncomed does

oncomed is a privately held, for-profit pharmaceutical manufacturer founded in 2010 and headquartered in Brno, Czech Republic. The company produces cytostatic injections — cell-growth-inhibiting injectable therapeutics used in the treatment of patients with oncological (cancer) diseases. Its core offering sits within the specialty/cytotoxic injectable segment of oncology pharmaceuticals, typically supplied into hospital and clinical oncology settings rather than retail pharmacy channels.

The firm operates at a mid-sized scale with a workforce of 101–250 employees, suggesting it has meaningful manufacturing capacity but remains a niche or regional player rather than a top-tier global oncology pharmaceutical firm. Cytostatic injectables require sterile manufacturing facilities, GMP certification, and regulatory oversight from bodies such as the Czech State Institute for Drug Control (SÚKL) and, for any EU-wide distribution, the European Medicines Agency (EMA). No specific product names, pipeline assets, regulatory approvals, technology platforms, pricing mechanisms, distribution arrangements, or customer relationships are documented in the available source material. The company's website (oncomed.cz) provides no substantive operational content beyond a loading/verification page, and no funding rounds, investors, leadership bios, or M&A activity are on record.

The revenue model is not disclosed, but for a cytostatic injectable manufacturer of this size and geography, the most likely model is B2B sales of finished injectable products (and possibly contract manufacturing) to hospital pharmacies, oncology centers, and potentially wholesale distributors within the Czech Republic and adjacent EU markets. Margin profiles in cytotoxic injectable manufacturing are typically supported by specialized handling requirements and regulatory complexity, which limits generic substitution but also constrains addressable scale.

Name

oncomed

Website

https://oncomed.cz

Company type

Private

Founded year

2010

Headcount range

101–250 employees

Short description

oncomed is a Czech Republic-based pharmaceutical manufacturer founded in 2010 that produces cytostatic (cell-growth-inhibiting) injections for the treatment of oncology patients, operating from Brno with 101–250 employees.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAAAC

Oncology & Hematology Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIACAA

Oncology Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Cytostatic injections
• Oncology pharmaceuticals
• Chemotherapy drugs
• Oncology medications
• Antineoplastic injectables

Headquarters

HQ city

Brno

HQ country

Czechia

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Core offering

Oncomed manufactures cytostatic injections used for the treatment of patients suffering from oncological diseases. The company operates as a pharmaceutical manufacturer producing injectable chemotherapy agents for cancer care.

Differentiator

Problem solved

Functional benefit

Products and services

• Cytostatic Injections

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Broad incumbents

• Viatris: Viatris (formed from Mylan and Upjohn) is a global pharmaceutical manufacturer with oncology injectable capabilities. Functions as a broad incumbent overlapping with oncomed's cytostatic manufacturing focus.
• Stada Arzneimittel: Stada is a European generic pharmaceutical manufacturer headquartered in Germany with specialty oncology injectable capabilities. Comparable as an EU-headquartered broad incumbent with similar cytostatic injection product lines.
• Sandoz: Sandoz, the Novartis generics division, is a global pharmaceutical manufacturer with a broad portfolio including oncology injectables. Functions as a broad incumbent that overlaps with oncomed's cytostatic injectable manufacturing offering but across a much wider portfolio.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with a meaningful oncology injectable portfolio. Functions as a broad incumbent offering comparable cytostatic and oncology injectable products across global markets.

Regional players

• Zentiva: Zentiva is a Czech-headquartered pharmaceutical manufacturer (originally Sanofi generics spin-off) producing generics including oncology injectables. Directly comparable as a CEE-based pharmaceutical manufacturer with overlapping capabilities.
• Egis Pharmaceuticals: Egis is a Hungary-based Central European pharmaceutical manufacturer with a portfolio that includes oncology products. Comparable as a regional CEE specialty pharmaceutical manufacturer serving similar hospital channels.

Direct peers

• Fresenius Kabi: Fresenius Kabi is a global leader in injectable pharmaceutical manufacturing with a substantial oncology injectable portfolio, including cytostatic products. Directly comparable to oncomed as a manufacturer of sterile injectable oncology drugs to hospital customers.
• Hikma Pharmaceuticals: Hikma is a major generic injectable pharmaceutical manufacturer with a focused oncology injectable portfolio, supplying hospitals globally. Directly comparable as a specialty generic injectable manufacturer with cytotoxic manufacturing capabilities.
• Dr. Reddy's Laboratories: Dr. Reddy's is a major Indian-headquartered pharmaceutical manufacturer with a meaningful oncology injectable portfolio serving global markets. Directly comparable as a specialty generic oncology injectable manufacturer.
• Aurobindo Pharma: Aurobindo is a major Indian-headquartered generic pharmaceutical manufacturer with a growing oncology injectable portfolio. Directly comparable as an emerging-to-mid specialty injectable manufacturer with cytotoxic capabilities.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/oncomed-manufacturing-a-s

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about oncomed